Abstract
From May 1978 until November 1980, 169 previously untreated patients with advanced epithelial ovarian cancer were entered into a prospective randomized clinical trial comparing the combination of hexamethylmelamine, Adriamycin, and cyclophosphamide (HAC) to a combination of melphalan and cis-platinum. Eleven patients were excluded from analysis and another 5 patients were excluded from response analysis. Of 153 patients evaluable for response, there were 47, or 30.7%, complete responders (all determined surgically), 6 partial responders, and 100 nonresponders. The response rate for the HAC group was 31% and for the melphalan-platinum group was 37.8%. The overall response rate was 34.6%. Residual tumor diameter (less than or greater than 2 cm) exerted a statistically significant effect on response--47.8 vs 24.4%. Of the 47 complete responders, 7, or 14.9%, have relapsed, with the median duration of remission of 44+ months. Of the 158 patients evaluable for survival, 90 patients have died, with a median survival time of 27.9 months (HAC = 26.4 months, melphalan-platinum = 29.6 months). Age, FIGO stage, histologic grade, and residual disease all exerted a significant effect on survival time. Second-line therapy in the treatment fa...Continue Reading
References
Nov 1, 1978·Cancer·B L JohnsonR C Young
Feb 1, 1978·Cancer·N Einhorn
Mar 1, 1977·Gynecologic Oncology·C R StanhopeF Rutledge
Jul 28, 1977·The New England Journal of Medicine·R R ReimerR C Young
Mar 1, 1978·Obstetrics and Gynecology·M S PiverL E Blumenson
Sep 1, 1976·Cancer·J P SmithF Rutledge
Dec 1, 1972·Cancer·J P SmithJ T Wharton
Jun 1, 1968·Clinical Obstetrics and Gynecology·D G DeckerC E Johnson
Apr 1, 1983·Gynecologic Oncology·L J CopelandJ Herson
Jul 15, 1981·Cancer·J T Wharton, J Herson
Oct 15, 1981·The New England Journal of Medicine·R J GrallaC W Young
Jan 1, 1980·Cancer·J Pedersen-BjergaardC Rose
Feb 1, 1980·Cancer·R F OzolsR C Young
Aug 15, 1980·Cancer·L M ParkerE Frei
Jun 1, 1965·Biometrika·E A GEHAN
Citations
Jan 1, 1992·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·U Abel
Aug 1, 1995·Critical Reviews in Oncology/hematology·P J Hoskins
Feb 21, 1985·The New England Journal of Medicine·G S RichardsonJ H Nelson
Apr 1, 1990·British Journal of Obstetrics and Gynaecology·J MasdingA P Menday
Feb 24, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M O NicolettoUNKNOWN Goccne Group (Gruppo Oncologico Cooperativo Clinico Nord-est), Padua, Italy
Apr 1, 1984·American Journal of Obstetrics and Gynecology·J T WhartonF N Rutledge
Feb 1, 1992·American Journal of Obstetrics and Gynecology·R W HunterW P Soutter
Mar 1, 1989·Gynecologic Oncology·D M GershensonR S Freedman
Oct 5, 2001·Gynecologic Oncology·K TamakoshiH Toyoshima
Jan 1, 1991·Leukemia & Lymphoma·A SulkesA Polliack
Oct 1, 1985·Gynecologic Oncology·J A CarlsonB J Masterson
Mar 1, 1985·Gynecologic Oncology·P F ConteG Pescetto
Mar 1, 1985·Cancer·D M GershensonF N Rutledge
Nov 1, 1991·Cancer·G L FrommW Scott
Jan 15, 1985·Cancer·L J CopelandF N Rutledge
Feb 15, 1990·International Journal of Cancer. Journal International Du Cancer·M SawadaK Endo
Jan 15, 1993·Cancer·D M GershensonJ T Wharton
Sep 1, 1988·Gynecologic Oncology·K C PodratzT O Wilson